Repository logo
 

Inhibition of Translation Initiation by Protein 169: A Vaccinia Virus Strategy to Suppress Innate and Adaptive Immunity and Alter Virus Virulence.


Change log

Authors

Strnadova, Pavla 
Ren, Hongwei 
Valentine, Robert 
Mazzon, Michela 
Sweeney, Trevor R 

Abstract

Vaccinia virus (VACV) is the prototypic orthopoxvirus and the vaccine used to eradicate smallpox. Here we show that VACV strain Western Reserve protein 169 is a cytoplasmic polypeptide expressed early during infection that is excluded from virus factories and inhibits the initiation of cap-dependent and cap-independent translation. Ectopic expression of protein 169 causes the accumulation of 80S ribosomes, a reduction of polysomes, and inhibition of protein expression deriving from activation of multiple innate immune signaling pathways. A virus lacking 169 (vΔ169) replicates and spreads normally in cell culture but is more virulent than parental and revertant control viruses in intranasal and intradermal murine models of infection. Intranasal infection by vΔ169 caused increased pro-inflammatory cytokines and chemokines, infiltration of pulmonary leukocytes, and lung weight. These alterations in innate immunity resulted in a stronger CD8+ T-cell memory response and better protection against virus challenge. This work illustrates how inhibition of host protein synthesis can be a strategy for virus suppression of innate and adaptive immunity.

Description

Keywords

Adaptive Immunity, Animals, CD8-Positive T-Lymphocytes, Cell Line, Female, Gene Deletion, Gene Expression Regulation, Host-Pathogen Interactions, Humans, Immunity, Innate, Immunologic Memory, Mice, Inbred BALB C, Mice, Inbred C57BL, Peptide Chain Initiation, Translational, Recombinant Fusion Proteins, Recombinant Proteins, Ribosome Subunits, Large, Eukaryotic, Ribosome Subunits, Small, Eukaryotic, Vaccinia, Vaccinia virus, Viral Proteins, Virulence

Journal Title

PLoS Pathog

Conference Name

Journal ISSN

1553-7366
1553-7374

Volume Title

11

Publisher

Public Library of Science (PLoS)
Sponsorship
Biotechnology and Biological Sciences Research Council (BB/G008205/1)
Medical Research Council (MR/M011747/1)
Biotechnology and Biological Sciences Research Council (BB/L000334/1)
Wellcome Trust (090315/Z/09/Z)
This work was supported by grants from the Wellcome Trust (090315) and the UK Medical Research Council (G0800151). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.